Summit Therapeutics Inc.
smmttx.comWhat Do They Do?
Develops oncology medicines for patients, with ivonescimab in clinical trials for lung and colorectal cancers.
10-K for FY2025, filed Feb 23, 2026Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and…View ↗
The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine…View ↗
The Company is developing ivonescimab in non-small cell lung cancer (“NSCLC”) and colorectal cancer (“CRC”), specifically conducting Phase…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 23, 2026
−$215.7MView ↗
- ▼ −62% (Loss)
- vs −$565.7M in Q2 FY2025
From anti-infectives to oncology
The older report included anti-infective programs and said ridinilazole development activities were being terminated; the latest centers on developing ivonescimab for oncology.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 23, 2026The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine…View ↗
Who Do They Compete With?
Competes with BioNTech, Bristol Myers Squibb, Pfizer, Merck, AbbVie, AstraZeneca, Daiichi Sankyo, and Johnson & Johnson
10-K for FY2025, filed Feb 23, 2026There are no known PD-1-based bispecific antibodies currently approved by the FDA, the European Medicines Agency (“EMA”), or Japan’s…View ↗
Loading...
